Business Standard

In race to stop Covid-19, Indian drugmakers to conduct clinical trials

Glenmark, Zydus Cadila to start trials in May

Civil defence officials wear protective suits to help a man who was lying on the roadside near Hebbal flyover during a nationwide lockdown imposed in the wake of novel coronavirus pandemic, in Bengaluru. Photo: PTI
Premium

Civil defence officials wear protective suits to help a man who was lying on the roadside near Hebbal flyover during a nationwide lockdown imposed in the wake of novel coronavirus pandemic, in Bengaluru. Photo: PTI

Sohini DasSamreen Ahmad Mumbai | Bengaluru
If the trials go along expected lines, we will soon have an antiviral drug (Favipiravir) for Covid-19 patients in the market.
Glenmark Pharmaceuticals is all set to start clinical trials on mild to moderate coronavirus-positive patients in May.
 
Meanwhile, several other Indian firms are stepping up efforts to start clinical trials on other drug candidates — such as biologic drug Interferon alfa-2b and antiviral drug Remdesivir.
 
Cadila Healthcare (Zydus Cadila) will start clinical trials on Interferon alfa-2b, a drug that it already makes commercially for Hepatitis C, for the novel coronavirus.

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Apr 30 2020 | 8:13 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com